BIOS Fund II, LP Amends IN8BIO, INC. Filing

TL;DR

BIOS Fund II, LP just updated their IN8BIO stake filing - something's changing.

AI Summary

On October 11, 2024, BIOS Fund II, LP and its affiliated entities filed an SC 13D/A amendment, reporting a change in beneficial ownership of IN8BIO, INC. The filing indicates a shift in control or strategy concerning the company's securities.

Why It Matters

This filing signals a potential shift in the investment strategy or control of IN8BIO, INC. by a significant shareholder group, which could impact the company's future direction.

Risk Assessment

Risk Level: medium — Amendments to SC 13D filings often indicate significant changes in a major shareholder's position or intentions, which can introduce uncertainty and volatility.

Key Players & Entities

• BIOS Fund II, LP (company) — Filing entity
• IN8BIO, INC. (company) — Subject company
• AARON GLENN (person) — Group member
• LOUIS FLETCHER (person) — Group member
• LESLIE WAYNE KREIS, JR. (person) — Group member

FAQ

Key Financial Figures

• $0.0001 — ame of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securitie

Filing Documents

• tm2425783d1_sc13da.htm (SC 13D/A) — 405KB
• 0001104659-24-108134.txt ( ) — 408KB

From the Filing

SC 13D/A 1 tm2425783d1_sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2) IN8bio, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45674E 109 (CUSIP Number) Bios Equity Partners, LP 1751 River Run, Suite 400 Fort Worth, Texas 76107 Tel: (817) 984-9197 With a Copy to: Rick Jordan Polsinelli PC 2950 N. Harwood St., Suite 2100 Dallas, Texas 75201 Tel: (214) 397-0030 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) October 4, 2024 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 45674E 109 1 NAME OF REPORTING PERSONS BIOS FUND II, LP 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) (b) 3 SEC USE ONLY 4 SOURCE OF FUNDS WC 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) 6 CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE, UNITED STATES NUMBER OF UNITS BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE VOTING POWER -0- 8 SHARED VOTING POWER 574,432 (1) 9 SOLE DISPOSITIVE POWER -0- 10 SHARED DISPOSITIVE POWER 574,432 (1) 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 574,432 (1) 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN UNITS 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0.8% (2) 14 TYPE OF REPORTING PERSON PN (1) Consists of 574,432 outstanding shares of common stock of the Issuer, par value $0.0001 per share (“Shares”), directly held by Bios Fund II, LP (“Bios Fund II”) as of the date hereof. (2) Based on 72,546,543 Shares, which consists of (i) 46,786,948 Shares outstanding as of August 7, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 8, 2024, and (ii) 25,759,595 Shares issued in connection with a private placement that closed on October 4, 2024 (the “PIPE Shares”). B-1 CUSIP No. 45674E 109 1 NAME OF REPORTING PERSONS BIOS FUND II QP, LP 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) (b) 3 SEC USE ONLY 4 SOURCE OF FUNDS WC 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) 6 CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE, UNITED STATES NUMBER OF UNITS BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE VOTING POWER -0- 8 SHARED VOTING POWER 1,876,624 (1) 9 SOLE DISPOSITIVE POWER -0- 10 SHARED DISPOSITIVE POWER 1,876,624 (1) 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,876,624 (1) 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN UNITS 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 2.6% (2) 14 TYPE OF REPORTING PERSON PN (1) Consists of 1,876,624 Shares directly held by Bios Fund II QP, LP (“Bios Fund II QP”) as of the date hereof. (2) Based on 72,546,543 Shares, which consists of (i) 46,786,948 Shares outstanding as of August 7, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 8, 2024, and (ii) the PIPE Shares. B-2 CUSIP No. 45674E 109 1 NAME OF REPORTING PERSONS BIOS FUND II NT, LP 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) (b) 3 SEC USE ONLY 4 SOURCE OF FUNDS WC 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) ¨ 6 CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE, UNITED STATES NUMBER OF UNITS BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE VOTING POWER -0- 8 SHARED VOTING POWER 251,211 (1) 9 SOLE DISPOSITIVE POWER -0- 10 SHARED DISPOSITIVE POWER 251,211 (1) 11 AGGREGATE AMOUNT BENEFICIALLY OWN

View Full Filing

View this SC 13D/A filing on SEC EDGAR